{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T22:26:15Z","timestamp":1762899975085,"version":"3.45.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.euo.2020.07.006","type":"journal-article","created":{"date-parts":[[2020,8,23]],"date-time":"2020-08-23T16:12:49Z","timestamp":1598199169000},"page":"1006-1010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Neoadjuvant Chemotherapy or Immunotherapy for Clinical T2N0 Muscle-invasive Bladder Cancer: Time to Change the Paradigm?"],"prefix":"10.1016","volume":"4","author":[{"given":"Filippo","family":"Pederzoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Bandini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Marandino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Raggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Giannatempo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Salonia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Gallina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2020.07.006_bib0150","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.euo.2019.06.002","article-title":"Can biomarkers guide the use of neoadjuvant chemotherapy in T2 bladder cancer?","volume":"2","author":"Grossman","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2020.07.006_bib0155","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s00345-019-02916-2","article-title":"How to improve patient selection for neoadjuvant chemotherapy in bladder cancer patients candidate for radical cystectomy and pelvic lymph node dissection","volume":"38","author":"Zamboni","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2020.07.006_bib0160","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.juro.2013.07.061","article-title":"Refining patient selection for neoadjuvant chemotherapy before radical cystectomy","volume":"191","author":"Culp","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2020.07.006_bib0165","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.eururo.2014.01.009","article-title":"Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides","volume":"67","author":"Reardon","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.07.006_bib0170","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.euo.2018.03.001","article-title":"Effectiveness of neoadjuvant chemotherapy for muscle-invasive bladder cancer in the current real world setting in the USA","volume":"1","author":"Hanna","year":"2018","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2020.07.006_bib0175","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1464-410X.2010.09442.x","article-title":"Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy","volume":"107","author":"Canter","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2020.07.006_bib0180","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.07.006_bib0185","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2020.07.006_bib0190","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1200\/JCO.2020.38.6_suppl.439","article-title":"Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy","volume":"38","author":"Gupta","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.07.006_bib0195","doi-asserted-by":"crossref","first-page":"viii726","DOI":"10.1093\/annonc\/mdy424.039","article-title":"LBA33\u2014A phase Ib\/II study of neoadjuvant pembrolizumab (pembro) and chemotherapy for locally advanced urothelial cancer (UC)","volume":"29","author":"Hoimes","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2020.07.006_bib0200","doi-asserted-by":"crossref","first-page":"v358","DOI":"10.1093\/annonc\/mdz249.003","article-title":"904PD\u2014Pre-operative ipilimumab and nivolumab in locoregionally advanced, stage III, urothelial cancer (NABUCCO)","volume":"30","author":"Van der Heijden","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2020.07.006_bib0205","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1200\/JCO.2017.76.9562","article-title":"Health-related quality-of-life analysis from KEYNOTE-045: a phase III study of pembrolizumab versus chemotherapy for previously treated advanced urothelial cancer","volume":"36","author":"Vaughn","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.07.006_bib0210","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2020.07.006_bib0215","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2020.07.006_bib0220","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3389\/fsurg.2018.00058","article-title":"Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer and its impact on surgical morbidity and oncological outcomes: a real-world experience","volume":"5","author":"Nguyen","year":"2018","journal-title":"Front Surg"},{"key":"10.1016\/j.euo.2020.07.006_bib0225","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.eururo.2014.01.014","article-title":"The effect of neoadjuvant chemotherapy on perioperative outcomes in patients who have bladder cancer treated with radical cystectomy: a population-based study","volume":"66","author":"Gandaglia","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.07.006_bib0230","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.eururo.2019.12.019","article-title":"Surgical safety of radical cystectomy and pelvic lymph node dissection following neoadjuvant pembrolizumab in patients with bladder cancer: prospective assessment of perioperative outcomes from the PURE-01 trial","volume":"77","author":"Briganti","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.07.006_bib0235","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1200\/JCO.2016.68.2518","article-title":"Updating the American Society of Clinical Oncology Value Framework: revisions and reflections in response to comments received","volume":"34","author":"Schnipper","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.07.006_bib0240","unstructured":"NICE. Glossary. https:\/\/www.nice.org.uk\/glossary?letter=q."},{"key":"10.1016\/j.euo.2020.07.006_bib0245","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.euo.2018.09.009","article-title":"Cost-effectiveness of pembrolizumab for patients with advanced, unresectable, or metastatic urothelial cancer ineligible for cisplatin-based therapy","volume":"2","author":"Patterson","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2020.07.006_bib0250","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.eururo.2019.10.026","article-title":"Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.07.006_bib0255","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.eururo.2020.01.003","article-title":"Comprehensive assessment of immuno-oncology biomarkers in adenocarcinoma, urothelial carcinoma, and squamous-cell carcinoma of the bladder","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.07.006_bib0260","first-page":"e846","article-title":"Mp55-20 Incongruence between TURB and radical cystectomy findings in terms of histological variant identification: analysis of all potential clinical risk factors","volume":"203","author":"Bandini","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2020.07.006_bib0265","doi-asserted-by":"crossref","unstructured":"Bandini M, Pederzoli F, Madison R, et al. Unfavorable cancer-specific survival after neoadjuvant chemotherapy and radical cystectomy in patients with bladder cancer and squamous cell variant: a multi-institutional study. Clin Genitourin Cancer. In press. https:\/\/doi.org\/10.1016\/j.clgc.2020.01.007.","DOI":"10.1016\/j.clgc.2020.01.007"},{"key":"10.1016\/j.euo.2020.07.006_bib0270","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.euo.2018.11.003","article-title":"Comparative effectiveness of treatment strategies for squamous cell carcinoma of the bladder","volume":"3","author":"Stensland","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2020.07.006_bib0275","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.eururo.2020.02.028","article-title":"Impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.07.006_bib0280","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.eururo.2018.04.029","article-title":"Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (Vesical Imaging-Reporting and Data System)","volume":"74","author":"Panebianco","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.07.006_bib0285","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.eururo.2019.12.016","article-title":"Multiparametric magnetic resonance imaging as a noninvasive assessment of tumor response to neoadjuvant pembrolizumab in muscle-invasive bladder cancer: preliminary findings from the PURE-01 study","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.07.006_bib0290","doi-asserted-by":"crossref","first-page":"e683","DOI":"10.1016\/S1470-2045(18)30693-4","article-title":"Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer","volume":"19","author":"Miyamoto","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931120301218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931120301218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:47:59Z","timestamp":1762876079000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931120301218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2588931120301218"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2020.07.006","relation":{},"ISSN":["2588-9311"],"issn-type":[{"type":"print","value":"2588-9311"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant Chemotherapy or Immunotherapy for Clinical T2N0 Muscle-invasive Bladder Cancer: Time to Change the Paradigm?","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2020.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}